Coronary disease & ACS

Prognostic Implications of Microvascular Resistance Reserve in Symptomatic Patients With Intermediate Coronary Stenosis

JACC Cardiovasc IntervPublished Prospective cohort study

Authors' conclusion

The presence of CMD defined by MRR was independently associated with the risk for a composite of cardiovascular death, myocardial infarction, repeat revascularization, and admission for heart failure in patients with stable IHD, irrespective of significant epicardial coronary artery stenosis.

Study context

Population
Patients undergoing echocardiographic and invasive physiological assessment for suspected stable ischemic heart disease (IHD)172 with fractional flow reserve (FFR) ≤0.80
Participants
547 patients
Exposure
Coronary microvascular dysfunction (CMD) vs no CMD, by FFR stratum
  • CMDn = 200
Outcome
Major adverse cardiovascular events (MACE):
  • CV death
  • MI
  • Repeat revascularization
  • HF admission
Follow-up
Median 3.3 years (Q1-Q3: 2.0-4.5 years)
Methodological detailsconsecutive patients
  • Consecutive patients

Main finding

As reported in the abstract

MACE · median 3.3 years
Estimate (95% CI)P value
MRRper 1-U decrease
HR 1.23(1.12–1.36)
P < 0.001
CMDvs No CMDFFR >0.80: 41.0% vs 26.0%
adjusted HR 1.59(1.07–2.35)
P = 0.021
CMDvs No CMDFFR ≤0.80: 34.7% vs 14.8%
adjusted HR 2.32(1.12–4.82)
P = 0.024

Observational data: associations, not effects.

Further findings

Correlations of microvascular resistance reserve (MRR)

MRR vs FFR, R = −0.031
P = 0.469
MRR vs index of microcirculatory resistance, R = −0.353
P < 0.001
MRR vs NT-proBNP, R = −0.296
P < 0.001
MRR vs LV filling pressure (E/e'), R = −0.224
P < 0.001
MRR vs diastolic dysfunction grade
P < 0.001

Original publication

Prognostic Implications of Microvascular Resistance Reserve in Symptomatic Patients With Intermediate Coronary Stenosis. JACC Cardiovasc Interv. Published 25 March 2024. doi:10.1016/j.jcin.2024.01.008

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.